Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 1/20 | 0.49 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.44 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.41 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.37 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.37 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.36 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.36 |
| ▸ | METAP1 | P53582 | 1/20 | 0.36 |
| ▸ | PRKDC | P78527 | 1/20 | 0.35 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.35 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.34 |
| ▸ | SMPD3 | Q9NY59 | 1/20 | 0.34 |
| ▸ | KDR | P35968 | 1/20 | 0.34 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.34 |
| ▸ | EGFR | P00533 | 1/20 | 0.34 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.33 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.33 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.32 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12761250 | 0.80 | GP6 (0.37) | — | |
| SCHEMBL15805858 | 0.80 | PDPK1 (0.72) | PDPK1CYP2A6LOXL2PTGDR2KAT6A | |
| SCHEMBL909645 | 0.79 | METAP1 (0.41) | PDPK1CYP2A6LOXL2METAP1ADRB2 | |
| SCHEMBL16159287 | 0.77 | PDPK1 (0.67) | PDPK1CYP2A6LOXL2PTGDR2KAT6A | |
| SCHEMBL4655029 | 0.74 | GP6 (0.49) | — | |
| SCHEMBL4425765 | 0.74 | PDPK1 (0.74) | PDPK1CYP2A6LOXL2PTGDR2KAT6A | |
| SCHEMBL12794006 | 0.73 | GP6 (0.58) | PDPK1CYP2A6 | |
| SCHEMBL20550702 | 0.73 | PDPK1 (0.60) | PDPK1CYP2A6LOXL2PTGDR2KAT6A | |
| SCHEMBL30060874 | 0.71 | PDPK1 (0.58) | PDPK1CYP2A6LOXL2PTGDR2KAT6A | |
| SCHEMBL16159315 | 0.71 | PDPK1 (0.58) | PDPK1CYP2A6LOXL2PTGDR2KAT6A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105001302-A | Cyclic peptide inhibitors of hepatitis C virus replication | INTERMUNE INC | 2015-10-28 | — | — | CN | disclosed |
| CN-102741270-B | Cyclic peptide inhibitors of hepatitis C virus replication | INTERMUNE INC | 2015-07-22 | — | — | CN | disclosed |
| CN-102741270-A | Cyclic peptide inhibitors of hepatitis c virus replication | INTERMUNE INC | 2012-10-17 | — | — | CN | disclosed |
| EP-2483290-A1 | CYCLIC PEPTIDE INHIBITORS OF HEPATITIS C VIRUS REPLICATION | Intermune, Inc. (US) | 2012-08-08 | — | — | EP | disclosed |
| US-20110081315-A1 | NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2011-04-07 | — | — | US | disclosed |
| WO-2011038293-A1 | CYCLIC PEPTIDE INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2011-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110081315-A1 | NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION | EIF2AK2, HAVCR2, EIF4A2 | PDPK1 2686/4885CYP2A6 403/4885LOXL2 3111/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.